Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Armata Pharmaceuticals (ARMP) EBITDA (2016 - 2018)

Armata Pharmaceuticals (ARMP) has disclosed EBITDA for 6 consecutive years, with -$1.1 million as the latest value for Q4 2018.

  • Quarterly EBITDA rose 53.45% to -$1.1 million in Q4 2018 from the year-ago period, while the trailing twelve-month figure was -$10.1 million through Dec 2018, up 37.56% year-over-year, with the annual reading at -$36.6 million for FY2025, 13.67% up from the prior year.
  • EBITDA hit -$1.1 million in Q4 2018 for Armata Pharmaceuticals, up from -$2.8 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $19.3 million in Q3 2014 to a low of -$12.0 million in Q1 2014.
  • Historically, EBITDA has averaged -$2.0 million across 5 years, with a median of -$2.9 million in 2015.
  • Biggest YoY gain for EBITDA was 221.59% in 2014; the steepest drop was 594.75% in 2014.
  • Year by year, EBITDA stood at -$2.6 million in 2014, then dropped by 13.21% to -$2.9 million in 2015, then plummeted by 303.54% to -$11.9 million in 2016, then surged by 80.07% to -$2.4 million in 2017, then soared by 53.45% to -$1.1 million in 2018.
  • Business Quant data shows EBITDA for ARMP at -$1.1 million in Q4 2018, -$2.8 million in Q3 2018, and -$3.2 million in Q2 2018.